Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary

The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrine practice 2020-10, Vol.26 (10), p.1196-1224
Hauptverfasser: Handelsman, Yehuda, Jellinger, Paul S, Guerin, Chris K, Bloomgarden, Zachary T, Brinton, Eliot A, Budoff, Matthew J, Davidson, Michael H, Einhorn, Daniel, Fazio, Sergio, Fonseca, Vivian A, Garber, Alan J, Grunberger, George, Krauss, Ronald M, Mechanick, Jeffrey I, Rosenblit, Paul D, Smith, Donald A, Wyne, Kathleen L
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The treatment of lipid disorders begins with lifestyle therapy to improve nutrition, physical activity, weight, and other factors that affect lipids. Secondary causes of lipid disorders should be addressed, and pharmacologic therapy initiated based on a patient's risk for atherosclerotic cardiovascular disease (ASCVD). Patients at extreme ASCVD risk should be treated with high-intensity statin therapy to achieve a goal low-density lipoprotein cholesterol (LDL-C) of
ISSN:1530-891X
1934-2403
DOI:10.4158/CS-2020-0490